阅读说明：本技术 一株可缓解和治疗冠心病的乳双歧杆菌Probio-M8及其应用 (Bifidobacterium lactis Probio-M8 capable of relieving and treating coronary heart disease and application thereof ) 是由 刘晓军 马杰 张凌宇 张建军 其木格苏都 杨慧娟 于 2020-05-25 设计创作，主要内容包括：本申请公开了一株可缓解和治疗冠心病的乳双歧杆菌Probio-M8及其应用。本申请通过临床人群试验表明,乳双歧杆菌Probio-M8安全性良好,可降低冠心病患者焦虑、抑郁情绪,缓解患者心绞痛症状,并降低血液中低密度脂蛋白胆固醇含量。对于缓解和治疗冠心病及焦虑、降低胆固醇水平具有明显效果,在制备缓解和治疗冠心病的产品和功能性产品中具有巨大的应用前景。(The application discloses a bifidobacterium lactis Probio-M8 strain capable of relieving and treating coronary heart disease and application thereof. Clinical population tests show that the bifidobacterium lactis Probio-M8 is good in safety, can reduce anxiety and depression mood of patients with coronary heart disease, relieve angina symptoms of the patients, and reduce the content of low-density lipoprotein cholesterol in blood. Has obvious effects on relieving and treating coronary heart disease and anxiety and reducing cholesterol level, and has huge application prospect in preparing products and functional products for relieving and treating coronary heart disease.)

1. The Bifidobacterium lactis Probio-M8 capable of relieving and treating coronary heart disease is characterized in that the Bifidobacterium lactis Probio-M8(Bifidobacterium lactis Probio-M8) is preserved in the China general microbiological culture Collection center at 09 and 20 months in 2019 with the preservation number of CGMCC No. 18610.

2. Use of bifidobacterium lactis Probio-M8 as claimed in claim 1 for the alleviation and treatment of coronary heart disease.

3. Use of bifidobacterium lactis Probio-M8 in a product for alleviating and treating coronary heart disease as claimed in claim 1, wherein the viable count of bifidobacterium lactis Probio-M8 is not less than 1.00 × 10⁶CFU/g or 1.00 × 10⁶CFU/mL。

4. Use according to claim 3, wherein the product comprises a food, pharmaceutical or nutraceutical product.

5. The use according to claim 4, wherein the health food comprises a ready-to-use starter, a probiotic solid beverage, a tabletted candy and functional pharmaceutical auxiliary materials.

6. The use according to claim 4, wherein the food product comprises a soy product, a dairy product or a fruit and vegetable product produced with a starter culture comprising Bifidobacterium lactis Probio-M8.

7. The use according to claim 4, wherein the medicament comprises a pharmaceutical carrier and/or a pharmaceutical excipient comprising the Bifidobacterium lactis Probio-M8.

8. Use of bifidobacterium lactis Probio-M8 as claimed in claim 1 for improving anxiety and depressed mood in patients with coronary heart disease.

9. Use of bifidobacterium lactis Probio-M8 in reducing cholesterol levels in patients with coronary heart disease as claimed in claim 1.

Technical Field

The application relates to the technical field of microorganisms, in particular to bifidobacterium lactis Probio-M8 capable of relieving and treating coronary heart disease and application thereof.

Background

Coronary atherosclerotic heart disease, coronary heart disease for short, is one of the common causes of death in cardiovascular disease. With the increasing incidence of coronary heart disease worldwide, the research on the pathogenesis and therapeutic measures of coronary heart disease is deepened. Hyperlipidemia, characterized by elevated levels of total cholesterol, triglycerides and low density lipoproteins and low levels of high density lipoproteins, can lead to atherosclerosis and thus coronary heart disease. Usually, patients with recessive coronary heart disease or coronary heart disease have fluctuating mood, often with mild depression or anxiety. In the occurrence and development of coronary heart disease, the blood lipid and inflammatory factor level play an important role, dyslipidemia is the most common and important factor for the onset of coronary heart disease, and the formation of atherosclerosis is a chronic inflammatory reaction with endothelial cell injury on the basis of lipid deposition. At present, the treatment method of coronary heart disease mainly comprises stent, bypass, medication and the like, which not only brings huge economic burden to patients, but also causes side effects of different degrees.

Probiotics have allowed their use in the clinical treatment of many diseases, and are generally defined as a group of active microorganisms that are capable of regulating and improving the intestinal flora and that have a promoting effect on human health when the body ingests sufficient amounts from the diet. There is a lack of probiotics that are effective in relieving and treating coronary heart disease, improving anxiety and depressed mood in patients, and reducing cholesterol levels.

Disclosure of Invention

The embodiment of the application provides a Bifidobacterium lactis Probio-M8 strain capable of relieving and treating coronary heart disease and application thereof, so as to solve the problem of lack of probiotics capable of effectively relieving and treating coronary heart disease, improving anxiety and depressed mood of patients and reducing cholesterol level.

In a first aspect, the application provides a Bifidobacterium lactis Probio-M8 strain capable of relieving and treating coronary heart disease, wherein the Bifidobacterium lactis Probio-M8(Bifidobacterium lactis Probio-M8) is separated from breast milk of a healthy woman, and the strain is deposited in the China general microbiological culture Collection center with the preservation number of CGMCC No. 18610; classified and named as Bifidobacterium lactis (Bifidobacterium lactis); preservation time: 09 month and 20 days 2019; and (4) storage address: western road No.1, north west city of township, beijing, institute of microbiology, china academy of sciences; the survival of the strain was detected.

The bifidobacterium lactis Probio-M8 is a gram-positive bacterium, and the agar plate generates a convex milky colony with the diameter of 1-2mm, the edge is complete, and the surface is smooth. The cell shape is dumbbell shaped bacillus, two ends are regular, and a plurality of obvious nodes are arranged, and the bifidobacterium Probio-M8 is heterotypic fermentation.

In a second aspect, the application provides the use of bifidobacterium lactis Probio-M8 for the alleviation and treatment of coronary heart disease.

Further, the application of the bifidobacterium lactis Probio-M8 in a product for relieving and treating coronary heart disease is realized, and the viable count of the bifidobacterium lactis Probio-M8 in the product is not less than 1.00 × 10⁶CFU/g or 1.00 × 10⁶CFU/mL。

Further, the product includes a food, a medicine or a health food.

Further, the health food comprises a direct vat set starter, a probiotic solid beverage, a tablet candy and functional medicine auxiliary materials.

Further, the food comprises a bean product, a dairy product or a fruit and vegetable product which is produced by a leavening agent containing the bifidobacterium lactis Probio-M8.

Further, the medicine comprises a medicine carrier and/or a pharmaceutic adjuvant containing the bifidobacterium lactis Probio-M8.

Further, the pharmaceutical excipients comprise a solvent, a propellant, a solubilizer, a cosolvent, an emulsifier, a colorant, an adhesive, a disintegrant, a filler, a lubricant, a wetting agent, an osmotic pressure regulator, a stabilizer, a glidant, a flavoring agent, a preservative, a suspending agent, a coating material, a flavoring agent, an anti-adhesive, an integrating agent, a penetration enhancer, a pH value regulator, a buffering agent, a plasticizer, a surfactant, a foaming agent, an antifoaming agent, a thickening agent, a coating agent, a humectant, an absorbent, a diluent, a flocculating agent and a deflocculating agent, a filter aid and a release retardant.

Further, the dosage form of the medicine comprises granules, capsules, tablets, pills or oral liquid.

In a third aspect, the application provides the use of bifidobacterium lactis Probio-M8 for improving anxiety and depressed mood in patients with coronary heart disease.

Further, the application of the bifidobacterium lactis Probio-M8 in a product for improving anxiety and depressed mood of patients with coronary heart disease, wherein the viable count of the bifidobacterium lactis Probio-M8 in the product is not less than 1.00 × 10⁶CFU/g or 1.00 × 10⁶CFU/mL。

Further, the product includes a food, a medicine or a health food.

Further, the health food comprises a direct vat set starter, a probiotic solid beverage, a tablet candy and functional medicine auxiliary materials.

Further, the food comprises a bean product, a dairy product or a fruit and vegetable product which is produced by a leavening agent containing the bifidobacterium lactis Probio-M8.

Further, the medicine comprises a medicine carrier and/or a pharmaceutic adjuvant containing the bifidobacterium lactis Probio-M8.

Further, the pharmaceutical excipients comprise a solvent, a propellant, a solubilizer, a cosolvent, an emulsifier, a colorant, an adhesive, a disintegrant, a filler, a lubricant, a wetting agent, an osmotic pressure regulator, a stabilizer, a glidant, a flavoring agent, a preservative, a suspending agent, a coating material, a flavoring agent, an anti-adhesive, an integrating agent, a penetration enhancer, a pH value regulator, a buffering agent, a plasticizer, a surfactant, a foaming agent, an antifoaming agent, a thickening agent, a coating agent, a humectant, an absorbent, a diluent, a flocculating agent and a deflocculating agent, a filter aid and a release retardant.

Further, the dosage form of the medicine comprises granules, capsules, tablets, pills or oral liquid.

In a fourth aspect, the present application provides the use of bifidobacterium lactis Probio-M8 for reducing cholesterol levels in patients with coronary heart disease.

Further, the application of the bifidobacterium lactis Probio-M8 in a product for reducing the cholesterol level of a coronary heart disease patient, wherein the viable count of the bifidobacterium lactis Probio-M8 in the product is not less than 1.00 × 10⁶CFU/g or 1.00 × 10⁶CFU/mL。

Further, the product includes a food, a medicine or a health food.

Further, the health food comprises a direct vat set starter, a probiotic solid beverage, a tablet candy and functional medicine auxiliary materials.

Further, the food comprises a bean product, a dairy product or a fruit and vegetable product which is produced by a leavening agent containing the bifidobacterium lactis Probio-M8.

Further, the medicine comprises a medicine carrier and/or a pharmaceutic adjuvant containing the bifidobacterium lactis Probio-M8.

Further, the pharmaceutical excipients comprise a solvent, a propellant, a solubilizer, a cosolvent, an emulsifier, a colorant, an adhesive, a disintegrant, a filler, a lubricant, a wetting agent, an osmotic pressure regulator, a stabilizer, a glidant, a flavoring agent, a preservative, a suspending agent, a coating material, a flavoring agent, an anti-adhesive, an integrating agent, a penetration enhancer, a pH value regulator, a buffering agent, a plasticizer, a surfactant, a foaming agent, an antifoaming agent, a thickening agent, a coating agent, a humectant, an absorbent, a diluent, a flocculating agent and a deflocculating agent, a filter aid and a release retardant.

Further, the dosage form of the medicine comprises granules, capsules, tablets, pills or oral liquid.

The application provides a Bifidobacterium lactis Probio-M8 strain capable of relieving and treating coronary heart disease and application thereof. Clinical population tests show that the bifidobacterium lactis Probio-M8 is good in safety, can reduce anxiety and depression mood of patients with coronary heart disease, relieve angina symptoms of the patients, and reduce the content of low-density lipoprotein cholesterol in blood. Has obvious effects on relieving and treating coronary heart disease and anxiety and reducing cholesterol level, and has huge application prospect in preparing products and functional products for relieving and treating coronary heart disease.

Drawings

In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the drawings needed to be used in the embodiments will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present application, and it is obvious for those skilled in the art to obtain other drawings without creative efforts.

Figure 1 is the anxiety self-scoring scale score results;

figure 2 is a depression self-rating scale score result;

FIG. 3 is a graph of the score for the activity limitation portion of the Seattle angina scale;

FIG. 4 is a graph of the results of the steady state score for angina in the Seattle angina scale;

FIG. 5 is a graph of the results of the scores for the onset of angina in the Seattle angina scale;

FIG. 6 is the results of the scores in the treatment satisfaction score part of the Seattle angina rating scale;

FIG. 7 is the score results of the cognitive score part of the Seattle angina rating scale;

FIG. 8 the effect of Bifidobacterium lactis Probio-M8 on low density lipoprotein cholesterol in patients with coronary heart disease;

FIG. 9 the effect of Bifidobacterium lactis Probio-M8 on serum interleukin 6 in patients with coronary heart disease.

Detailed Description

The application provides a Bifidobacterium lactis Probio-M8 capable of relieving and treating coronary heart disease, wherein the Bifidobacterium lactis Probio-M8(Bifidobacterium lactis Probio-M8) is separated from breast milk of healthy women and is a probiotic strain with good gastrointestinal fluid and bile salt tolerance, and the strain is preserved in the China general microbiological culture Collection center with the preservation number of CGMCC No. 18610; classified and named as bifidobacterium lactis (Bifidobacterium lactis); preservation time: 09 month and 20 days 2019; and (4) storage address: western road No.1, north west city of township, beijing, institute of microbiology, china academy of sciences; the survival of the strain was detected.

The application provides application of bifidobacterium lactis Probio-M8 in relieving and treating coronary heart disease.

Further, the application of the bifidobacterium lactis Probio-M8 in a product for relieving and treating coronary heart disease is realized, and the viable count of the bifidobacterium lactis Probio-M8 in the product is not less than 1.00 × 10⁶CFU/g or 1.00 × 10⁶CFU/mL。

Further, the product includes a food, a medicine or a health food.

Further, the health food comprises a direct vat set starter, a probiotic solid beverage, a tablet candy and functional medicine auxiliary materials.

Further, the food comprises a bean product, a dairy product or a fruit and vegetable product which is produced by a leavening agent containing the bifidobacterium lactis Probio-M8.

Further, the medicine comprises a medicine carrier and/or a pharmaceutic adjuvant containing the bifidobacterium lactis Probio-M8.

Further, the pharmaceutical excipients comprise a solvent, a propellant, a solubilizer, a cosolvent, an emulsifier, a colorant, an adhesive, a disintegrant, a filler, a lubricant, a wetting agent, an osmotic pressure regulator, a stabilizer, a glidant, a flavoring agent, a preservative, a suspending agent, a coating material, a flavoring agent, an anti-adhesive, an integrating agent, a penetration enhancer, a pH value regulator, a buffering agent, a plasticizer, a surfactant, a foaming agent, an antifoaming agent, a thickening agent, a coating agent, a humectant, an absorbent, a diluent, a flocculating agent and a deflocculating agent, a filter aid and a release retardant.

Further, the dosage form of the medicine comprises granules, capsules, tablets, pills or oral liquid.

The application provides application of bifidobacterium lactis Probio-M8 in improving anxiety and depressed mood of patients with coronary heart disease.

Further, the application of the bifidobacterium lactis Probio-M8 in a product for improving anxiety and depressed mood of patients with coronary heart disease, wherein the viable count of the bifidobacterium lactis Probio-M8 in the product is not less than 1.00 × 10⁶CFU/g or 1.00 × 10⁶CFU/mL。

Further, the product includes a food, a medicine or a health food.

Further, the health food comprises a direct vat set starter, a probiotic solid beverage, a tablet candy and functional medicine auxiliary materials.

Further, the food comprises a bean product, a dairy product or a fruit and vegetable product which is produced by a leavening agent containing the bifidobacterium lactis Probio-M8.

Further, the medicine comprises a medicine carrier and/or a pharmaceutic adjuvant containing the bifidobacterium lactis Probio-M8.

Further, the pharmaceutical excipients comprise a solvent, a propellant, a solubilizer, a cosolvent, an emulsifier, a colorant, an adhesive, a disintegrant, a filler, a lubricant, a wetting agent, an osmotic pressure regulator, a stabilizer, a glidant, a flavoring agent, a preservative, a suspending agent, a coating material, a flavoring agent, an anti-adhesive, an integrating agent, a penetration enhancer, a pH value regulator, a buffering agent, a plasticizer, a surfactant, a foaming agent, an antifoaming agent, a thickening agent, a coating agent, a humectant, an absorbent, a diluent, a flocculating agent and a deflocculating agent, a filter aid and a release retardant.

Further, the dosage form of the medicine comprises granules, capsules, tablets, pills or oral liquid.

The application provides application of bifidobacterium lactis Probio-M8 in reducing cholesterol level of patients with coronary heart disease.

Further, the application of the bifidobacterium lactis Probio-M8 in a product for reducing the cholesterol level of a coronary heart disease patient, wherein the viable count of the bifidobacterium lactis Probio-M8 in the product is not less than 1.00 × 10⁶CFU/g or 1.00 × 10⁶CFU/mL。

Further, the product includes a food, a medicine or a health food.

Further, the health food comprises a direct vat set starter, a probiotic solid beverage, a tablet candy and functional medicine auxiliary materials.

Further, the food comprises a bean product, a dairy product or a fruit and vegetable product which is produced by a leavening agent containing the bifidobacterium lactis Probio-M8.

Further, the medicine comprises a medicine carrier and/or a pharmaceutic adjuvant containing the bifidobacterium lactis Probio-M8.

Further, the pharmaceutical excipients comprise a solvent, a propellant, a solubilizer, a cosolvent, an emulsifier, a colorant, an adhesive, a disintegrant, a filler, a lubricant, a wetting agent, an osmotic pressure regulator, a stabilizer, a glidant, a flavoring agent, a preservative, a suspending agent, a coating material, a flavoring agent, an anti-adhesive, an integrating agent, a penetration enhancer, a pH value regulator, a buffering agent, a plasticizer, a surfactant, a foaming agent, an antifoaming agent, a thickening agent, a coating agent, a humectant, an absorbent, a diluent, a flocculating agent and a deflocculating agent, a filter aid and a release retardant.

Further, the dosage form of the medicine comprises granules, capsules, tablets, pills or oral liquid.

In order to prove that the bifidobacterium lactis Probio-M8 can relieve and treat coronary heart disease, improve anxiety and depressed mood of patients and reduce cholesterol level, the following experiments are carried out.

Experimental example 1 clinical trial of Bifidobacterium lactis Probio-M8 for treating coronary heart disease

The test of the bifidobacterium lactis Probio-M8 for treating the patient with coronary heart disease is carried out for 6 months, and 60 volunteers are recruited, the test is divided into a probiotic group and a placebo group, the probiotic group takes basic treatment medicaments (aspirin, statin lipid-lowering medicaments, metoprolol, isosorbide dinitrate and the like) for the coronary heart disease and the bifidobacterium lactis Probio-M8(3.00 × 10)¹⁰CFU/day), the placebo group takes basic drugs (aspirin, statin lipid-lowering drugs, metoprolol, isosorbide dinitrate, etc.) for treating coronary heart disease and placebo.

Clinical data include six blood indicators of anxiety and depression status, angina status and low density lipoprotein cholesterol, serum interleukin 6, glutamic-pyruvic transaminase, blood urea nitrogen, creatinine, and white blood cell count. Two clinical data collections were performed at the beginning and end of the trial, respectively, and a differential Test between the probiotic and placebo groups was performed using the Wilcoxon Test.

Volunteer status:

A. probiotic group

a. In total, 36 persons: 19 men, 17 women;

b. average age: 64.80 plus or minus 8.03 years old;

c. average BMI: 25.08 +/-2.13;

d. coronary heart disease typing: 24 people are unstable angina, 9 people are stable angina and 3 people are acute myocardial infarction;

e. number of coronary stents: 16 people did not mount a stent, 6 people one stent, 8 people two stents, 6 people three stents.

B. Placebo group

a. A total of 24 persons: 14 men, 10 women;

b. average age: 66.29 ± 10.30 years old;

c. average BMI: 25.55 plus or minus 2.04;

d. coronary heart disease typing: 17 people are unstable angina, 6 people are stable angina and 1 person is acute myocardial infarction;

e. number of coronary stents: no support was installed for 9 people, one support for 5 people, two supports for 7 people, and three supports for 3 people.

The patients in the probiotic group and the placebo group had no significant difference in age, BMI and average scaffold number. Acute Coronary Syndrome (ACS) is unstable angina and Acute myocardial infarction, the ACS proportion of the probiotic group is 75.00%, the ACS proportion of the placebo group is 75.00%, and the proportions of the probiotic group and the placebo group are the same.

The results are as follows:

1. bifidobacterium lactis Probio-M8 for improving symptoms of anxiety and depression of patients with coronary heart disease

Anxiety and depression were assessed using the Self-rating anxiety Scale (SAS) and Self-rating depression Scale (SDS), respectively, with higher scores on the SAS and SDS scales indicating greater anxiety and depression, and two clinical questionnaires at the beginning and end of the trial, respectively.

As shown in fig. 1, when bifidobacterium lactis Probio-M8 was taken until the end of treatment, the SAS scale score of the probiotic group (Probiotics) was significantly lower than that of the Placebo group (Placebo) (P <0.0001), the SAS scale score of the probiotic group was significantly reduced before and after treatment (P <0.0001), from 46.31 before treatment to 38.43 after treatment, which was reduced by 17.01%, and the difference in score reduction before and after treatment was not significant in the Placebo group. As shown in fig. 2, the SDS scale score of the probiotic group was significantly lower than that of the placebo group (P <0.0001) by the end of the treatment after the administration of bifidobacterium lactis Probio-M8, the SDS scale score of the probiotic group was significantly reduced (P <0.0001) before and after the treatment, the score was reduced by 21.05% from 49.34 before the treatment to 38.95 after the treatment, and the score was reduced to a smaller extent and was not significantly different before and after the treatment of the placebo group.

The left side of the same data set is Before treatment (Before treatment) and the right side is after treatment (after treatment).

In conclusion, the anxiety and depression mood of the patient with coronary heart disease can be remarkably relieved by taking the bifidobacterium lactis Probio-M8.

2. Bifidobacterium lactis Probio-M8 for improving angina pectoris symptoms of coronary heart disease patients

Angina pectoris status was assessed using the Seattle angina pectoris Scale (SAQ). The SAQ scale is composed of 19 subjects, and is divided into five parts, wherein the first part is 'activity limitation degree', the second part is 'angina pectoris stable state', the third part is 'angina pectoris attack condition', the fourth part is 'treatment satisfaction degree score', the fifth part is 'cognition degree score', the lower the score is, the more serious the symptoms of angina pectoris are, the worse the treatment effect is.

As shown in fig. 3-7, the intra-group analysis found that the scores of the five partial problems on the SAQ scale were significantly increased before and after treatment (P <0.0001) in both the probiotic and placebo groups, indicating that the patients taking both the probiotic and placebo groups could alleviate the symptoms of angina pectoris. Analysis between groups found significant differences between the pre-treatment "activity limited" (P ═ 0.015) and "cognition score" (P ═ 0.033) probiotic groups versus placebo, and the remaining three problems were not significant differences between the pre-treatment probiotic groups and placebo groups. The difference of the 'activity limitation degree' scores between the probiotic group and the placebo group is very obvious (P is 0.00014) by taking the bifidobacterium lactis Probio-M8 to the end of the treatment, but the score of the probiotic group is increased by 44.40%, and the score of the placebo group is only increased by 10.80%, which indicates that the activity limitation degree of the bifidobacterium lactis Probio-M8 for patients with coronary heart disease is improved better than that of the placebo; the difference in "cognition score" between the probiotic group and the placebo group after treatment was no longer significant, indicating that bifidobacterium lactis Probio-M8 improved the patient's cognition better than that of placebo; the "angina pectoris steady state" (P ═ 0.00015), "angina pectoris episode (P <0.0001), and" treatment satisfaction score "(P ═ 0.00090) scores were all very significantly higher after treatment than the placebo group.

In conclusion, the bifidobacterium lactis Probio-M8 has better treatment effect and treatment satisfaction on angina.

3. Effect of Bifidobacterium lactis Probio-M8 on blood of patients with coronary heart disease

Blood samples are pretreated, and the full spectrum of the samples is measured in a non-targeting way through an LC-MS technology so as to determine metabolic difference substances among different treatment groups.

Blood markers include Low Density Lipoprotein cholesterol (LDL-C), serum Interleukin 6(Interleukin-6, IL-6), Glutamate pyruvate transaminase (Glutamate Pyrvictransami), Blood Urea Nitrogen (Blood Urea Nitrogen), Creatinine (Creatinine), and white Blood Cell Count (Whiteblood Cell Count). LDL-C is the main lipoprotein in fasting plasma, is the main carrier for transporting cholesterol to extrahepatic tissues, and has obvious positive correlation with the incidence rate of coronary heart disease, so that the lower the concentration of LDL-C is, the lower the incidence risk of coronary heart disease is; IL-6 is a lymphokine produced by activated T cells and fibroblasts, is an important inflammatory marker, and as an index for predicting early basic lesions and severe complications of acute coronary syndrome, the higher the IL-6 serum concentration, the higher the risk of developing severe coronary sclerosis and recurrent angina. Glutamate pyruvate transaminase is mainly present in liver cells, and is released into blood in large amount in the acute stage of various viral hepatitis and in the case of toxic liver cell necrosis, so that it is an important index for diagnosing viral hepatitis and toxic hepatitis. Blood urea nitrogen is a nitrogen-containing compound in plasma except for proteins, is filtered from glomeruli and excreted, and is an auxiliary examination method for examining whether the urination function is normal or not. Creatinine is a product of muscle metabolism in the human body and can reflect the filtering function of glomeruli. The leucocyte has the functions of phagocytizing foreign matters and generating antibodies, the healing capacity of body injury, the capacity of resisting pathogen invasion, the immunity resistance to diseases and the like, and the higher the leucocyte count is, the higher the possibility of bacterial infection in vivo is, the inflammation is shown. Wherein, the glutamic-pyruvic transaminase, blood urea nitrogen, creatinine and leukocyte counts are the indexes of drug safety.

As shown in fig. 8 and fig. 9, the in-group comparative analysis shows that the LDL-C and IL-6 contents in blood of the probiotic group and the placebo group are very significantly reduced (P <0.0001) before and after treatment, which indicates that the cholesterol and inflammatory factors contents in blood of coronary heart disease patients can be reduced by taking the medicine of the probiotic group and the placebo group. Analysis among groups shows that the contents of LDL-C and IL-6 in blood before treatment have no significant difference, and the contents of LDL-C and IL-6 in blood of the probiotic group are extremely lower than those of the placebo group (P <0.0001, and P ═ 0.0014) by taking the bifidobacterium lactis Probio-M8 until the end of treatment. Glutamate pyruvate transaminase, blood urea nitrogen, creatinine and white blood cell counts were not significantly different between the probiotic group and the placebo group, as shown in table 1.

TABLE 1 blood indices

In conclusion, the administration of Bifidobacterium lactis Probio-M8 can reduce LDL-C and IL-6 in blood of patients with coronary heart disease, and further reduce the risk of coronary heart disease; the bifidobacterium lactis Probio-M8 has good safety and no negative influence on liver function, kidney function and blood routine.

According to the scheme, the application provides the Bifidobacterium lactis Probio-M8 capable of relieving and treating the coronary heart disease and the application thereof. Clinical population tests show that the bifidobacterium lactis Probio-M8 is good in safety, can reduce anxiety and depression mood of patients with coronary heart disease, relieve angina symptoms of the patients, and reduce the content of low-density lipoprotein cholesterol in blood. Has obvious effects on relieving and treating coronary heart disease and anxiety and reducing cholesterol level, and has huge application prospect in preparing products and functional products for relieving and treating coronary heart disease.

Other embodiments of the present application will be apparent to those skilled in the art from consideration of the specification and practice of the application disclosed herein. This application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the application and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the application being indicated by the following claims.

It will be understood that the present application is not limited to the precise arrangements described above and shown in the drawings and that various modifications and changes may be made without departing from the scope thereof. The scope of the application is limited only by the appended claims.